StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Each row shows where CGEM sits in our scored universe today on a single observational measurement. P85 means CGEM ranks above 85% of peers on that factor right now. Percentile rankings are descriptive — they are not buy/sell signals or quality judgments. Universe refreshed every 60 seconds.
Today's volume vs prior session average.
Absolute daily price move vs peers.
24h article count relative to the universe.
AI-classified polarity of recent news.
Today's dollar turnover (volume × VWAP).
Signed daily return vs the rest of the universe.
Stonvex publishes percentile measurements as observational data only. Nothing here constitutes a recommendation, prediction, or advice about whether to buy, sell, or hold any security. Stonvex is not a registered investment advisor.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-08 | $14.61 | $14.55 | -0.41% | 0.6M |
| 05-11 | $14.74 | $14.73 | -0.07% | 0.9M |
| 05-12 | $14.72 | $16.15 | +9.71% | 1.9M |
| 05-13 | $16.00 | $16.33 | +2.06% | 1.0M |
| 05-14 | $16.24 | $16.34 | +0.62% | 0.2M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Annual 2022 2022-12-31 | Q3 2022 2022-09-30 | Q2 2022 2022-06-30 | Q1 2022 2022-03-31 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $144.65M | $177.26M | $207.02M | $-32.66M |
Net Income | $111.21M | $138.00M | $162.80M | $-12.10M |
EPS (Diluted) | $2.38 | $2.96 | $3.51 | $-0.27 |
Total Assets | $561.12M | $617.24M | $667.25M | $437.46M |
Total Liabilities | $26.09M | $31.11M | $62.63M | $17.99M |
Cash & Equivalents | $156.15M | $242.66M | $353.56M | $76.12M |
Free Cash Flow OCF − CapEx | $-127.80M | $-101.93M | $-47.33M | $-21.91M |
Shares Outstanding | 45.80M | 45.74M | 45.40M | 44.66M |
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
What you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
What drives CGEM's price movement
Watch headlines closely. This stock reacts strongly to news catalysts. Set news alerts.
Moderate news sensitivity
Moderate sentiment influence
Low volume impact — moves on other factors
Underperforming peers — laggard in sector
Not momentum-driven — mean-reverts quickly
Low flow signal — not institutional-driven
DNA analysis is based on current factor scoring. Not investment advice.
Quiet session — no dominant driver
Research only. Labels above describe the current state of the stock using price, volume, and news data — they are not buy or sell recommendations. Stonvex is not a registered investment advisor. Past market behavior does not imply future results.